Should You Buy Phio Pharmaceuticals Corp (PHIO) Stock After it Has Risen 1.06% in a Week?

Overall market sentiment has been high on Phio Pharmaceuticals Corp (PHIO) stock lately. PHIO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Phio Pharmaceuticals Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PHIO!

See Full PHIO Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With PHIO Stock Today?

Phio Pharmaceuticals Corp (PHIO) stock is down -11.23% while the S&P 500 is up 0.6% as of 9:46 AM on Thursday, Mar 21. PHIO is lower by -$0.12 from the previous closing price of $1.07 on volume of 301,558 shares. Over the past year the S&P 500 is higher by 31.30% while PHIO is lower by -83.07%. PHIO lost -$8.17 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Phio Pharmaceuticals Corp click here.

More About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others. Click Here to get the full Stock Report for Phio Pharmaceuticals Corp stock.